Home | Welcome to Contract Pharma   
Last Updated Monday, October 20 2014
Print

Financial Report: Gilead Sciences



Published February 3, 2012
Gilead Sciences

4Q Revenues: $2.2 billion (+10%)

4Q Earnings: $665.1 million (+6%)

FY Revenues: $8.4 billion (+5%)

FY Earnings: $2.8 billion (-3%)

Comments: Antiviral product sales were up 9% to $1.9 billion in the quarter and up 8% to $7.1 billion for the year. Sales of Atripla were $863.3 million in the quarter (+11%) and $3.2 billion for the year (+10%). Sales of Truvada were $746.0 million in the quarter (+9%) and $2.9 billion for the year (+8%). Sales of Viread were flat at $190.9 million in the quarter and up 1% to $737.9 million for the year. Sales of Letairis were $78.7 million in the quarter (+23%) and $293.4 million for the year (+22%). Sales of Ranexa were up 23% in the quarter to $83.7 million and up 33% to $320.0 million for the year. Royalty, contract and other revenues from collaborations were $67.0 million in the quarter (-2%) and $283.0 million for the year (-49%), primarily due to lower Tamiflu royalties from Roche.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On